Transcatheter Cardiovascular Therapeutics 2004 Meeting In Brief
This article was originally published in The Gray Sheet
Executive Summary
Guidant SPIRITed by study results: MACE rate of 7.7% at six months for Guidant's drug-eluting stent is slightly higher - but statistically comparable - to rates associated with J&J/Cordis' Cypher and Boston Scientific's Taxus. At the Sept. 27-Oct. 1 TCT 2004 conference in Washington, D.C., Guidant releases six-month data from the 60-patient, randomized, single-blind SPIRIT-FIRST trial, showing angiographic in-stent late loss of 0.10 mm for the everolimus-elutingversion of the MultiLink Vision stent, versus 0.84 mm for bare-metal. Both of the major adverse cardiac events (2/23) linked to the DES occurred within the first 30 days, with no new events out to six months, Guidant notes. SPIRIT-FIRST tests a cobalt-chromium, durable-polymer stent system - a departure from Guidant's FUTURE trials assessing a stainless-steel stent platform with bioabsorbable-polymer. The study supports an IDE filing for a pivotal trial (1"The Gray Sheet" Sept. 20, 2004, p. 6)...
You may also be interested in...
Third Quarter 2004 Earnings In Brief
Epic growth proportions?: St. Jude Medical expects ICD sales of $570 mil.-$580 mil. in 2004. Reporting on the first full quarter with Epic HF and Atlas + HF CRT defibrillators on the market, the firm notes total ICD sales of $157 mil. in Q3, a 57% climb over the 2003 period. During the quarter, St. Jude extended its atrial fibrillation therapy portfolio, acquiring Irvine Medical and entering a purchase deal with Endocardial Solutions (1"The Gray Sheet" Sept. 27, 2004, p. 9). Earnings rose from $84 mil. in Q3 2003 to $91 mil. in Q3 2004, based on $578 mil. in sales, which represented 22% growth over last year. St. Jude took a special charge of $35 mil. for discontinuing Symmetry bypass aortic connectors...
Third Quarter 2004 Earnings In Brief
Epic growth proportions?: St. Jude Medical expects ICD sales of $570 mil.-$580 mil. in 2004. Reporting on the first full quarter with Epic HF and Atlas + HF CRT defibrillators on the market, the firm notes total ICD sales of $157 mil. in Q3, a 57% climb over the 2003 period. During the quarter, St. Jude extended its atrial fibrillation therapy portfolio, acquiring Irvine Medical and entering a purchase deal with Endocardial Solutions (1"The Gray Sheet" Sept. 27, 2004, p. 9). Earnings rose from $84 mil. in Q3 2003 to $91 mil. in Q3 2004, based on $578 mil. in sales, which represented 22% growth over last year. St. Jude took a special charge of $35 mil. for discontinuing Symmetry bypass aortic connectors...
Guidant Awaits SPIRIT Trial Data For Clear Vision Of Future Stent Business
Feasibility data on the Multi-Link Vision cobalt-chromium, durable-polymer, everolimus-eluting stent will be key to predicting the stability of Guidant's DES technology platform in the post-Dollens era